Orgenesis Inc. (ORGS)
| Market Cap | 3.43M -47.8% |
| Revenue (ttm) | 1.04M +95.3% |
| Net Income | -48.17M |
| EPS | -11.44 |
| Shares Out | 9.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Open | 0.0327 |
| Previous Close | 0.3500 |
| Day's Range | 0.0327 - 0.9100 |
| 52-Week Range | 0.0010 - 1.0000 |
| Beta | 3.35 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 13, 2026 |
About Orgenesis
Orgenesis Inc., a biotech company, focuses on cell and gene therapies in the United States. It operates through two segments: Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare model, POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic d... [Read more]
Financial Performance
In 2024, Orgenesis's revenue was $1.04 million, an increase of 95.28% compared to the previous year's $530,000. Losses were -$48.17 million, -13.00% less than in 2023.
Financial StatementsNews
Orgenesis Proxy statement: Proxy filing
Orgenesis filed a proxy statement on May 20, 2026, providing details for shareholder voting and corporate governance matters.
Orgenesis Proxy statement: Proxy filing
Orgenesis filed a proxy statement on May 5, 2026, providing details for shareholder voting and corporate governance matters.
Orgenesis Proxy statement: Proxy filing
Orgenesis filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Okogen Acquires Ranpirnase Assets and Intellectual Property Portfolio
Plano, Texas--(Newsfile Corp. - March 26, 2026) - Okogen Inc., a biotechnology company developing antiviral therapeutics, today announced the acquisition of the global intellectual property portfolio ...
Orgenesis Annual report: Q4 2024
Orgenesis has published its Q4 2024 annual report on March 26, 2026.
Orgenesis Inc. Announces Acquisition of Certain Neurocords LLC Assets, Strengthening its Regenerative Medicine Portfolio with Spinal Cord Injury Therapies
Strategic Acquisition Designed to Expand Access to Cost-Effective, Scalable Regenerative Medicine Treatments GERMANTOWN, MD / ACCESS Newswire / March 6, 2025 / Orgenesis Inc . (OTCQX:ORGS) ("Orgenesis...
Orgenesis secures $5M equity investment from Williamsburg Venture
Orgenesis (ORGS) has concluded an agreement for an equity line of credit of up to $5M from Williamsburg Venture Holdings. Under the terms of the agreement, Orgenesis will receive $750,000…
Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture Holdings
Funding Aimed at Accelerating Rollout of Decentralized CGT Platform GERMANTOWN, MD / ACCESS Newswire / January 28, 2025 / Orgenesis Inc . (OTCQX:ORGS) ("Orgenesis" or the "Company"), a global biotech ...
Orgenesis reports Q3 EPS ($1.93) vs. (12c) last year
Reports Q3 revenue $347,000 vs. $110,000 last year. Vered Caplan, CEO of Orgenesis (ORGS), stated, “Orgenesis is making significant progress in redefining accessibility to cell and gene therapies thro...
Orgenesis Quarterly report: Q3 2024
Orgenesis has published its Q3 2024 quarterly earnings report on November 13, 2024.
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Orgenesis (ORGS), 546% surge in interest Cyclacel Pharmac...
Orgenesis commences trading on OTCQX Best Market
Orgenesis (ORGS) announced that its common stock will begin trading on the OTCQX Best Market under the ticker symbol “ORGS” following its delisting from the Nasdaq Stock Market. The delisting…
Orgenesis trading halted, news pending
19:50 EDT Orgenesis trading halted, news pending
Orgenesis board approves 1-for-10 reverse stock split
Orgenesis Board of Directors has approved a 1-for-10 reverse stock split of the Company’s common stock, par value $0.0001, which will be effective at 5:00 pm Eastern Time on September…
Orgenesis announces results for study of CD19 CAR-T therapy
Orgenesis announced positive clinical trial results for a real-world study of CD19 CAR-T therapy, ORG-101, in patients with CD19+ Acute Lymphoblastic Leukemia. Harley Street Healthcare Group intends t...
Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia
Orgenesis' CD19 CAR-T therapy, ORG-101, had a complete response (CR) of 82% in adults and 93% in pediatric patients with the incidence of severe Cytokine Release Syndrome (CRS) of 2% in adult patient...
Orgenesis announces JV partnership with Harley Street Healthcare Group
Orgenesis announced a strategic partnership agreement with Harley Street Healthcare Group. This partnership aims to accelerate the clinical development and commercialization of advanced wellness and l...
Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally
The strategic alliance aims to drive new-age innovation in wellness & longevity, backed by an investment commitment of up to $10 million over 3 years into both Orgenesis and the newly formed joint ven...
Orgenesis reports Q2 EPS (23c) vs. (76c) last year
Reports Q2 revenue $246K, one $165k .Vered Caplan, CEO of Orgenesis, stated, “After more than a decade of parallel efforts-on one hand, establishing robust capabilities in cell therapy production by…
Orgenesis Quarterly report: Q2 2024
Orgenesis has published its Q2 2024 quarterly earnings report on August 8, 2024.
Orgenesis agrees to purchase assets from Broaden Bioscience
In a regulatory filing, Orgenesis disclosed that on July 10, the company entered into an Asset Purchase Agreement with Broaden Bioscience and Technology for the purchase by the company of…
Orgenesis files to sell 2.475M shares of common stock for holders
16:08 EDT Orgenesis files to sell 2.475M shares of common stock for holders
Orgenesis Registration statement: Registration Filing
Orgenesis filed a registration statement on June 6, 2024, providing details about a securities offering with the SEC.
Orgenesis Registration statement: Registration Filing
Orgenesis filed a registration statement on May 24, 2024, providing details about a securities offering with the SEC.
Orgenesis reports Q1 EPS (29c) vs (87c) last year
Reports Q1 revenue $141,000 vs $142,000 last year. Vered Caplan, CEO of Orgenesis, said, “We continue to advance the commercialization of our decentralized platform through Octomera, our strategic CGT...